cdn mobile

Region 7 receives 1st shipment of 300 doses of Sputnik V

By: Morexette Marie B. Erram - Multimedia Reporter - CDN Digital | June 02,2021 - 12:33 PM

| PTV Cebu photo

CEBU CITY, Philippines – Central Visayas on Wednesday, June 2, received its first shipment of Sputnik V COVID-19 vaccines.

Dr. Mary Jean Loreche, spokesperson of the Department of Health in Central Visayas (DOH-7), confirmed in a series of messages sent to reporters that the region has been allocated with 300 ampoules of the vaccine.

“One ampoule (is equivalent to) one dose,” said Loreche.

Loreche also said the newly arrived vaccines, manufactured by Russia’s Gamaleya Research Institute, will be administered to individuals listed under the subgroups A1 to A3, which refer to medical frontliners, senior citizens, and persons with comorbidities.

| PTV Cebu photo

She added that the current allocation of the Russian-made vaccines is intended for the first dose.  The next shipment will be set aside for the second dose.

The 300 doses of Sputnik V delivered to Central Visayas is part of the initial shipment of 15,000 doses intended for the Philippines. / dcb

RELATED STORIES:

Region 7 receives 1st shipment of Pfizer COVID

34 hospitals to get initial batch of Pfizer vaccine — DOH

Full rollout for second-dose vaccines starts on May 10

 

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Read Next

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

TAGS: Central Visayas, DOH-7, Sputnik V
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.